

# **Z-DEVD-FMK**

**Catalog No: tcsc3454** 

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

**Specifications** 

### CAS No:

210344-95-9

## Formula:

C <sub>30</sub> H	$_{41}^{H}F$	N <sub>4</sub> C	)
		· · · · · · · · · · · · · · · · · · ·	

#### Pathway:

Apoptosis

# **Target:**

Caspase

Form:

#### Purity / Grade:

>98%

#### Solubility:

DMSO : ≥ 33.33 mg/mL (49.85 mM)

#### **Storage Instruction:**

Powder -20°C 3 years, 4°C 2 years ; In solvent -80°C 6 months ;-20°C 1 month

#### **Alternative Names:**

Caspase-3 Inhibitor

Copyright 2021 Taiclone Biotech Corp.



#### **Observed Molecular Weight:**

668.66


# **Product Description**

Z-DEVD-FMK is a specific and irreversible **caspase-3** inhibitor with  $IC_{50}$  of 18  $\mu$ M.

```
IC50 & Target: IC50: 18 µM (caspase-3)<sup>[1]</sup>
```

*In Vitro:* N27 cells are exposed to MPP<sup>+</sup> in the absence or presence of 50  $\mu$ M Z-DIPD-FMK or 100  $\mu$ M Z-DEVD-FMK or 50  $\mu$ M Z-LEHD-FMK and then caspase-9 and caspase-3 enzymatic activities are determined by enzymatic assay at 12 and 24 h following exposure, respectively. Exposure to 300  $\mu$ M MPP<sup>+</sup> for 24 h in N27 cells results in an approximately 2.5-fold increase in caspase-3 enzyme activity. MPP<sup>+</sup>-induced increases in caspase-3 enzyme activity are significantly blocked by 50  $\mu$ M Z-DIPD-FMK, 100  $\mu$ M Z-DEVD-FMK, and 50  $\mu$ M Z-LEHD-FMK<sup>[1]</sup>.

*In Vivo:* Early Z-DEVD-FMK (160 ng) treatment improves motor and cognitive function after traumatic CNS injury induced by severe controlled cortical impact (CCI) in the mouse<sup>[2]</sup>. Treatment with Z-DEVD-FMK (160 ng) significantly improves neurological outcome when compared with traumatized animals treated with DMSO vehicle (p[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.